Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Sajith RaghunandananDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-4526-307X
Raj PriyaDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Gaofeng LinDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Fuad AlanaziDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0009-0001-5328-6239
Andrew ZossDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Elise WarrenDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Philip StewartBiology of Vector-Borne Viruses Section, Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
X Frank YangDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-7231-3167
Funding
Regulatory Network of the Lyme Disease PathogenR01AI083640 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI X. Frank Yang · 2009 to 2026
$5.9M
Targeting Cyclic Dinucleotide Signaling Pathways to Interrupt the Nature Cycle of Borrelia burgdorferiR01AI152235 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI SINTIM, HERMAN O, YANG, X. FRANK · 2020 to 2024
$3.4M
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR015481 · NCRR · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI FIFE, ROSE S · 2001 to 2001
$1.6M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI083640, AI152235NCRR NIH HHS C06 RR015481NIAID NIH HHS R01 AI083640NIAID NIH HHS R01 AI152235
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Positive feedback regulation between RpoS and BosR in the Lyme disease pathogen. · full record | OpenQuestion